Company intelligence / Profile preview

Concordia

Ahmedabad/Dholka/Limbasi/Valthera, Gujarat, Indiaconcordiacollege.edu ↗

Ownership: Private
Employees: ~1180
Development stage: Other

Overview

Concord Biotech has commercialized over two decades of expertise in fermentation-based APIs and finished formulations. It supplies products globally across more than 70 countries. The company recently commissioned a new injectable facility and received ANDA approval for teriflunomide. It continues to expand its pipeline with both generic APIs/formulations and contract manufacturing services for global partners.

Therapeutic areas: OncologyImmunologyNephrologyInfectious Diseases
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Works with leading global pharmaceutical companies for API supply and contract development/manufacturing services; specific partners not named in public disclosures.

Beyond the preview

Go deeper on Concordia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Concordia.

Explore the full profile